Sprint Bioscience AB (publ)

Stockholm Stock Exchange SPRINT.ST

Sprint Bioscience AB (publ) Price to Earnings Ratio (P/E) on January 14, 2025: -221.61

Sprint Bioscience AB (publ) Price to Earnings Ratio (P/E) is -221.61 on January 14, 2025, a -31.79% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Sprint Bioscience AB (publ) 52-week high Price to Earnings Ratio (P/E) is -122.84 on February 05, 2024, which is 44.57% above the current Price to Earnings Ratio (P/E).
Sprint Bioscience AB (publ) 52-week low Price to Earnings Ratio (P/E) is -319.83 on October 24, 2024, which is -44.32% below the current Price to Earnings Ratio (P/E).
Sprint Bioscience AB (publ) average Price to Earnings Ratio (P/E) for the last 52 weeks is -203.25.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Stockholm Stock Exchange: SPRINT.ST

Sprint Bioscience AB (publ)

CEO	Mr. Johan Emilsson
IPO Date	Nov. 7, 2014
Location	Sweden
Headquarters	Novum
Employees	36
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.

Key trends

Past 5 years